134 related articles for article (PubMed ID: 31529538)
1. Predictors of graft survival at diagnosis of antibody-mediated renal allograft rejection: a retrospective single-center cohort study.
Waiser J; Klotsche J; Lachmann N; Wu K; Rudolph B; Halleck F; Liefeldt L; Bachmann F; Budde K; Duerr M
Transpl Int; 2020 Feb; 33(2):149-160. PubMed ID: 31529538
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
Lachmann N; Duerr M; Schönemann C; Pruß A; Budde K; Waiser J
J Immunol Res; 2017; 2017():6872046. PubMed ID: 28255562
[TBL] [Abstract][Full Text] [Related]
3. Treatment of antibody-mediated rejection of kidney grafts with bortezomib and/or rituximab compared to standard regimen: experience of Slovene National Center.
Oblak T; Lindič J; Gubenšek J; Kveder R; Aleš Rigler A; Škoberne A; Večerić Haler Ž; Borštnar Š; Avguštin N; Ponikvar R; Mlinšek G; Ferluga D; Kojc N; Godnov U; Kovač D
Clin Nephrol; 2017 Supplement 1; 88(13):91-96. PubMed ID: 28664838
[TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.
Bachelet T; Nodimar C; Taupin JL; Lepreux S; Moreau K; Morel D; Guidicelli G; Couzi L; Merville P
Clin Transplant; 2015 May; 29(5):439-46. PubMed ID: 25739833
[TBL] [Abstract][Full Text] [Related]
5. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
6. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection.
Piñeiro GJ; De Sousa-Amorim E; Solé M; Ríos J; Lozano M; Cofán F; Ventura-Aguiar P; Cucchiari D; Revuelta I; Cid J; Palou E; Campistol JM; Oppenheimer F; Rovira J; Diekmann F
BMC Nephrol; 2018 Oct; 19(1):261. PubMed ID: 30309322
[TBL] [Abstract][Full Text] [Related]
7. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
9. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
10. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection.
Kikić Ž; Kainz A; Kozakowski N; Oberbauer R; Regele H; Bond G; Böhmig GA
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1435-43. PubMed ID: 26071493
[TBL] [Abstract][Full Text] [Related]
11. Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.
Viglietti D; Loupy A; Aubert O; Bestard O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Jouven X; Delahousse M; Kamar N; Lefaucheur C
J Am Soc Nephrol; 2018 Feb; 29(2):606-619. PubMed ID: 29255058
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
13. Human Pooled Immunoglobulin as Treatment of Active Antibody-Mediated Rejection of Transplanted Kidney.
Furmańczyk-Zawiska A; Urbanowicz A; Perkowska-Ptasińska A; Bączkowska T; Sadowska A; Nazarewski S; Chmura A; Durlik M
Transplant Proc; 2016 Jun; 48(5):1446-50. PubMed ID: 27496425
[TBL] [Abstract][Full Text] [Related]
14. Early Estimated Glomerular Filtration Rate Trajectories After Kidney Transplant Biopsy as a Surrogate Endpoint for Graft Survival in Late Antibody-Mediated Rejection.
Borski A; Kainz A; Kozakowski N; Regele H; Kläger J; Strassl R; Fischer G; Faé I; Wenda S; Kikić Ž; Bond G; Reindl-Schwaighofer R; Mayer KA; Eder M; Wahrmann M; Haindl S; Doberer K; Böhmig GA; Eskandary F
Front Med (Lausanne); 2022; 9():817127. PubMed ID: 35530045
[TBL] [Abstract][Full Text] [Related]
15. Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts.
Loupy A; Vernerey D; Tinel C; Aubert O; Duong van Huyen JP; Rabant M; Verine J; Nochy D; Empana JP; Martinez F; Glotz D; Jouven X; Legendre C; Lefaucheur C
J Am Soc Nephrol; 2015 Jul; 26(7):1721-31. PubMed ID: 25556173
[TBL] [Abstract][Full Text] [Related]
16. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
18. Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab.
Mulley WR; Huang LL; Ramessur Chandran S; Longano A; Amos LAR; Polkinghorne KR; Nikolic-Paterson DJ; Kanellis J
Clin Transplant; 2017 Sep; 31(9):. PubMed ID: 28640458
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.
Kizilbash S; Claes D; Ashoor I; Chen A; Jandeska S; Matar RB; Misurac J; Sherbotie J; Twombley K; Verghese P
Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28092129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
